利妥昔单抗治疗抗肾小球基底膜病的疗效与安全性
该研究通过回顾病例报告和系列(n=28)并补充4项研究共18例患者数据,分析67例抗GBM病患者的个体资料。利妥昔单抗作为一线或二线治疗,患者生存率91%,肾脏生存率67%;初始透析依赖者肾脏生存率更低(34% vs 81%,P<0.001),二线使用优于一线(73% vs 46%,P=0.03)。结论提示利妥昔单抗安全性良好,可考虑作为环磷酰胺禁忌时的二线治疗。
要点
- 利妥昔单抗治疗抗GBM病总体耐受性良好,仅16%出现短暂不良反应。
- 初始即透析依赖者肾脏生存率显著低于非透析依赖者(34% vs 81%)。
- 二线使用利妥昔单抗的肾脏生存率优于一线使用(73% vs 46%)。
核心结论
- 利妥昔单抗在抗GBM病中具有较好的安全性和疗效,可考虑作为环磷酰胺禁忌时的二线治疗。
研究设计与样本
- 回顾性分析28篇病例报告/系列,并补充4项研究共18例患者数据,共纳入67例成人和儿童抗GBM病患者。
主要发现
- 67例患者中位年龄37岁,女性55%,儿童21%,中位随访9.5个月,总随访87.1人年。
- 患者生存率91%,肾脏生存率67%(成人53%,儿童71%)。
- 初始透析依赖者肾脏生存率34%,非透析依赖者81%(P<0.001)。
- 二线利妥昔单抗肾脏生存率73%,一线为46%(P=0.03)。
- 16%患者出现短暂不良反应,中位利妥昔单抗剂量为4(2-4)次。
关键数值与推荐
- 利妥昔单抗中位剂量4(2-4)次,16%出现短暂不良反应。
- 患者生存率91%,肾脏生存率67%。
- 初始透析依赖者肾脏生存率34% vs 非透析依赖者81%(P<0.001)。
- 二线使用肾脏生存率73% vs 一线46%(P=0.03)。
临床怎么用
- 在环磷酰胺禁忌时,可考虑将利妥昔单抗作为抗GBM病的二线治疗。
- 初始即透析依赖的患者肾脏预后较差,需密切监测。
局限性
- 研究存在发表偏倚和选择偏倚。
- 样本量较小,随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Anti-glomerular basement membrane (GBM) disease is caused by pathogenic antibodies usually targeting the noncollagenous domain of the α3 chain of type IV collagen and frequently presents as rapidly progressive glomerulonephritis and diffuse alveolar hemorrhage (DAH). Rapid reduction of these antibodies is imperative for kidney survival and the mainstay of therapy is the combination of plasma exchange (PLEX), glucocorticoids, and cyclophosphamide. Rituximab has been postulated as a potential treatment for anti-GBM disease; however, data on efficacy and safety are lacking. METHODS: We performed a review of case reports and series (n = 28) providing individual patient-level data on the efficacy and safety of rituximab in adult and pediatric anti-GBM disease. In addition, we have received data from authors on 18 patients which stem from 4 studies that did not report on patient-level outcomes or were not previously reported. A search strategy of studies indexed in PubMed/MEDLINE was performed, followed by synthesis and analysis of the data. RESULTS: Sixty-seven patients [37 female (55%); 14 pediatric (21%); median age: 37 years] were followed-up with for a total of 87.1 person-years (median follow-up time: 9.5 months). They received rituximab as first-line (n = 39) or second-line (n = 28). Median serum creatinine was 416 μmol/l with 32 patients (48%) being dialysis-dependent at presentation and 24 (36%) having DAH. Intravenous pulse, oral glucocorticoids and PLEX were used in 85%, 98%, and 93%, respectively; and 54% of them received cyclophosphamide. Patients received a median of 4 (2-4) doses of rituximab with 11 patients (16%) having transient adverse effects. Patient survival was 91% and kidney survival was 67% (53% in adults and 71% in pediatric patients). Kidney survival was lower in initially dialysis-dependent patients (34% vs. 81%, P < 0.001). Patients receiving second-line rituximab had better kidney survival compared with those receiving it as first-line (73% vs. 46%, P = 0.03). CONCLUSION: Acknowledging the limitations of our study, including publication and selection bias, rituximab had a favorable toxicity and efficacy profile. The results indicate that rituximab can be considered as a second-line therapy in anti-GBM disease when cyclophosphamide is contraindicated.
引用
- Ivković V, Bajema I, Bruchfeld A, et al. Efficacy and Safety of Rituximab in Antiglomerular Basement Membrane Disease. Kidney Int Rep. 2024. PMID: 40225363. doi:10.1016/j.ekir.2024.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。